These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 18625856)
1. Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Steinerman JR; Irizarry M; Scarmeas N; Raju S; Brandt J; Albert M; Blacker D; Hyman B; Stern Y Arch Neurol; 2008 Jul; 65(7):906-12. PubMed ID: 18625856 [TBL] [Abstract][Full Text] [Related]
2. The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain. McDonald JM; Cairns NJ; Taylor-Reinwald L; Holtzman D; Walsh DM Brain Res; 2012 Apr; 1450():138-47. PubMed ID: 22440675 [TBL] [Abstract][Full Text] [Related]
3. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418 [TBL] [Abstract][Full Text] [Related]
4. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. Tremblay C; Pilote M; Phivilay A; Emond V; Bennett DA; Calon F J Alzheimers Dis; 2007 Dec; 12(4):377-90. PubMed ID: 18198424 [TBL] [Abstract][Full Text] [Related]
6. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234 [TBL] [Abstract][Full Text] [Related]
7. Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Murphy MP; Beckett TL; Ding Q; Patel E; Markesbery WR; St Clair DK; LeVine H; Keller JN Neurobiol Dis; 2007 Sep; 27(3):301-11. PubMed ID: 17651976 [TBL] [Abstract][Full Text] [Related]
8. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286 [TBL] [Abstract][Full Text] [Related]
9. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Xia W; Yang T; Shankar G; Smith IM; Shen Y; Walsh DM; Selkoe DJ Arch Neurol; 2009 Feb; 66(2):190-9. PubMed ID: 19204155 [TBL] [Abstract][Full Text] [Related]
10. The pathogenic aβ43 is enriched in familial and sporadic Alzheimer disease. Sandebring A; Welander H; Winblad B; Graff C; Tjernberg LO PLoS One; 2013; 8(2):e55847. PubMed ID: 23409063 [TBL] [Abstract][Full Text] [Related]
11. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842 [TBL] [Abstract][Full Text] [Related]
12. Association of Cortical β-Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. Yu L; Petyuk VA; Tasaki S; Boyle PA; Gaiteri C; Schneider JA; De Jager PL; Bennett DA JAMA Neurol; 2019 Jul; 76(7):818-826. PubMed ID: 31009033 [TBL] [Abstract][Full Text] [Related]